@article{4f1453e46d5545e5ab2003cad7518cc8,
title = "P2.03a-025 Randomized, Double-Blind, Phase 3 Study Comparing Biosimilar Candidate ABP 215 with Bevacizumab in Patients with Non-Squamous NSCLC: Topic: Clinical Trials",
author = "Nick Thatcher and Michael Thomas and Gyula Ostoros and Jean Pan and Jerome Goldschmidt and Michael Schenker and Vladimir Hanes",
note = "ABP 215 is a biosimilar candidate that is similar to bevacizumab, a VEGF inhibitor, in analytical and functional comparisons. Pharmacokinetic similarity between ABP 215 and bevacizumab has been demonstrated in a phase 1 study. Here we present results from a pivotal phase 3 clinical study in non-small-cell lung cancer (NSCLC).",
year = "2017",
month = jan,
day = "1",
doi = "10.1016/J.JTHO.2016.11.1234",
language = "American English",
volume = "12",
journal = "Journal of Thoracic Oncology",
number = "1",
}